Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Chronic Hepatitis C Infection: early-phase trial registry

A small indexed set (2 trials) with no open enrollment listed right now.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count

Chronic Hepatitis C Infection: 2 US clinical trials tracked, none currently recruiting.

Chronic Hepatitis C Infection is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is HanAll BioPharma Co., running 1 of these trials.

Enrollment posture brief

Registry condition chronic-hepatitis-c-infection

OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Chronic Hepatitis C Infe (this)Chronic Hepatitis C Infe (th…0%
Open-enrollment share among volume-matched conditions near Chronic Hepatitis C Infection

Chronic Hepatitis C Infection has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Hepatitis C Infection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Hepatitis C Infection is recruiting below its size-band peers.

    0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

AbbVie 1 trials

Named interventions

Most-linked intervention names on Chronic Hepatitis C Infection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ribavirin Drug
2 trials
Paritaprevir mini tablet Drug
1 trials
Ombitasvir mini tablet Drug
1 trials
Dasabuvir Drug
1 trials
Ombitasvir/paritaprevir/ritonavir Drug
1 trials
recombinant variant of interferon-alpha 2b Drug
1 trials
Peginterferon alfa-2a Drug
1 trials

US sites by state

Facility locations filed on Chronic Hepatitis C Infection trials. A trial with sites in several states counts in each.

Florida 2 trials
California 2 trials
Washington 1 trials
Texas 1 trials
Pennsylvania 1 trials
New York 1 trials
Massachusetts 1 trials
Louisiana 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chronic Hepatitis C Infection page

2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Chronic Hepatitis C Infection trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • HanAll BioPharma Co. sponsors the most Chronic Hepatitis C Infection trials on record, review their full trial history before evaluating a specific study. See HanAll BioPharma Co.'s trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Hepatitis C Infection condition card totals 2 registered trials; most-linked intervention Ribavirin; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.